Investigational Drug Information for Rubitecan
✉ Email this page to a colleague
What is the drug development status for Rubitecan?
Rubitecan is an investigational drug.
There have been 17 clinical trials for Rubitecan.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 1998.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and European Organisation for Research and Treatment of Cancer - EORTC.
Summary for Rubitecan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,808 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,584 |
| Clinical Trial Progress | Phase 2 (1998-11-01) |
| Vendors | 92 |
Recent Clinical Trials for Rubitecan
| Title | Sponsor | Phase |
|---|---|---|
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | Astex Pharmaceuticals | Phase 2/Phase 3 |
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | Astex Pharmaceuticals, Inc. | Phase 2/Phase 3 |
| Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | Astex Pharmaceuticals | Phase 1 |
Clinical Trial Summary for Rubitecan
Top disease conditions for Rubitecan
Top clinical trial sponsors for Rubitecan
US Patents for Rubitecan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
